medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2016, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2016; 32 (1)

Adoptive cell immunotherapy with blood cord lymphocites in viral infections post hematopoietic transplant

Rivero JRA

Language: Spanish
References: 20
Page: 125-131
PDF size: 93.79 Kb.


ABSTRACT

Viral reactivation predominantly occurs in the first 3-6 months after stem cell transplantation. The most clinically important are the herpes viruses; cytomegalovirus, Epstein-Barr virus and human herpes virus 6; the polyoma viruses BK and JC and adenovirus. Cellular adoptive immunotherapy is a treatment used to help immune system to fight against this kind of diseases. It is based on the extraction of specific T lymphocytes from an individual and its culture at the laboratory, to increase the number of T cells able to destroy viral targets, and these T cells are infused to the patient in order to help his immune system. In vitro experimental data suggest the high and perhaps unique potential of cord blood cells to generate biologically active products as therapeutic tools of this new type in order to facilitate graft, immunotherapy and regenerative medicine. A naive T cell phenotype derived from cord blood has been employed to reduce graft versus host disease after stem cell transplantation and as adoptive cellular immunotherapy with virus-specific cytotoxic T lymphocytes to prevent, in an effective way, this kind of viral infections.


REFERENCES

  1. Instituto Nacional del Cáncer. Diccionario del Cáncer. 2015. Disponible en: http://www.cancer.gov/espanol/publicaciones/diccionario?cdrid=285915. [Accedido: 12 de julio de 2015].

  2. Barrett AJ, Bollard CM. The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation. Ann Transl Med 2015;3(5):62.

  3. Jain NA, Lu K, Ito S, Muranski P, Hourigan CS, Haggerty J, et al. The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches. Cytotherapy. 2014;16:927-33.

  4. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:238-41.

  5. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994;331:679-80.

  6. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925-35.

  7. Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya- Feldstein J, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119:2644-56.

  8. Sellar RS, Peggs KS. Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update. Expert Opin Biol Ther. 2014;14:1121-6.

  9. Odendahl M, Grigoleit GU, Bönig H, Neuenhahn M, Albrecht J, Anderl F, et al. Clinical-scale isolation of “minimally manipulated” cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease. Cytotherapy. 2014;16:1245-56.

  10. Ramírez N, Olavarría E. Viral-specific adoptive immunotherapy after allo-SCT: the role of multimer-based selection strategies. Bone Marrow Transplant. 2013;48:1265-70.

  11. Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H, et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013;21:2113-21.

  12. Meij P, Jedema I, Zandvliet ML,>van der Heiden PL,>van de Meent M, >van Egmond HM, et al. Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines. J Immunother. 2012;35:621-8.

  13. Garcia Lopez J. Situación actual de los bancos de sangre de cordón umbilical y su utilidad terapéutica. Acta Científica Tecnológica. 2005(9):37-39.

  14. Rivero-Jiménez R. Razones para un banco de sangre de cordón umbilical en el Instituto de Hematología e Inmunología de Cuba. Rev Cubana Hematol Inmunol Hemoter. 2014;31(1):1-4.

  15. Sun Q, Burton RL, Pollok KE, Emanuel DJ, Lucas KG. CD4(+) Epstein-Barr virusspecific cytotoxic T-lymphocytes from human umbilical cord blood. Cell Immunol. 1999;195:81-8.

  16. Park KD, Marti L, Kurtzberg J, Szabolcs P. In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood. 2006;108:1770-3.

  17. Jedema I, van de Meent M, Pots J, Kester MG, van der Beek MT, Falkenburg JH. Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigenspecific precursor T cells and regulatory T cells. Haematologica. 2011;96:1204-12.

  18. Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114:1958-67.

  19. Breier DV, Querol S, García J. Alternativas terapéuticas en el post transplante: Inmunoterapia adoptiva especifica de sangre de cordón (SCU) umbilical en el post transplante de células progenitoras hematopoyéticas. Acta Científica y Tecnológica. 2006;(11):30-32. (Accedido 15/07/2015). Disponible en: http://www.aecientificos.es/escaparate/listarproductos.cgi?idcategoria=2631&refcom pra=NULO

  20. Einsele H. Hebart H. CMV-specific immunotherapy. Hum Immunol. 2004;65(5):558-64.




2020     |     www.medigraphic.com